Literature DB >> 8094803

Ondansetron for hallucinosis in advanced Parkinson's disease.

J Zoldan, G Friedberg, H Goldberg-Stern, E Melamed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8094803     DOI： 10.1016/0140-6736(93)90327-d

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

Review 1.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

2.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

Authors:  T Büttner; W Kuhn; T Müller; F L Welter; J Federlein; K Heidbrink; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

5.  Parkinson's psychosis.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

Review 6.  Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis.

Authors:  Harini Sarva; Claire Henchcliffe
Journal:  Ther Adv Neurol Disord       Date:  2016-10-03       Impact factor: 6.570

Review 7.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 8.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Treatment of psychosis in Parkinson's disease: safety considerations.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Joseph H Friedman
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 10.  Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  CNS Spectr       Date:  2008-03       Impact factor: 3.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.